Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.

Suppr

超能文献

作者信息

Reiter Lawrence A, Mitchell Peter G, Martinelli Gary J, Lopresti-Morrow Lori L, Yocum Sue A, Eskra James D

机构信息

Pfizer Inc, Global Reseach & Development, Groton Laboratories, Eastern Point Rd., 06340, Groton, CT, USA.

出版信息

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2331-6. doi: 10.1016/s0960-894x(03)00413-x.

DOI:10.1016/s0960-894x(03)00413-x

PMID:12824028

Abstract

Phosphinic acid-based inhibitors of MMP-13 have been investigated with the aim of identifying potent inhibitors with high selectivity versus MMP-1. Independent variation of the substituents on a P(1)' phenethyl group and a P(2) benzyl group improved potencies in both cases around 3-fold over the unsubstituted parent. Combining improved P(1)' and P(2) groups into a single molecule gave an inhibitor with a 4.5 nM IC(50) against MMP-13 and which is 270-fold selective over MMP-1.

摘要

相似文献

Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2331-6. doi: 10.1016/s0960-894x(03)00413-x.

Design and synthesis of conformationally-constrained MMP inhibitors.

Bioorg Med Chem Lett. 1998 Aug 18;8(16):2077-80. doi: 10.1016/s0960-894x(98)00370-9.

Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.

J Med Chem. 2001 Sep 13;44(19):3074-82. doi: 10.1021/jm010096n.

Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.

Bioorg Med Chem Lett. 1999 Jan 18;9(2):127-32. doi: 10.1016/s0960-894x(98)00729-x.

N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.

J Med Chem. 2001 Sep 13;44(19):3066-73. doi: 10.1021/jm010097f.

Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.

Bioorg Med Chem Lett. 1998 Apr 7;8(7):837-42. doi: 10.1016/s0960-894x(98)00125-5.

A quantitative structure-activity relationship study on some novel series of hydroxamic acid analogs acting as matrix metalloproteinase inhibitors.

Med Chem. 2007 Mar;3(2):167-73. doi: 10.2174/157340607780059477.

Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3389-95. doi: 10.1016/j.bmcl.2004.04.083.

N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.

J Med Chem. 2009 Aug 13;52(15):4757-73. doi: 10.1021/jm900261f.

Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.

J Med Chem. 1999 Jan 14;42(1):87-94. doi: 10.1021/jm980142s.

引用本文的文献

The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma.

Cells. 2019 Aug 27;8(9):984. doi: 10.3390/cells8090984.

Zymography as a Research Tool in the Study of Matrix Metalloproteinase Inhibitors.

Methods Mol Biol. 2017;1626:79-102. doi: 10.1007/978-1-4939-7111-4_8.

Is there new hope for therapeutic matrix metalloproteinase inhibition?

Nat Rev Drug Discov. 2014 Dec;13(12):904-27. doi: 10.1038/nrd4390. Epub 2014 Nov 7.

Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury.

Neurotherapeutics. 2011 Apr;8(2):206-20. doi: 10.1007/s13311-011-0038-0.

Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors.

J Am Chem Soc. 2007 Aug 29;129(34):10408-17. doi: 10.1021/ja0715849. Epub 2007 Aug 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验